113 related articles for article (PubMed ID: 24951349)
1. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson.
Fournier L; Ammari S; Thiam R; Cuénod CA
Diagn Interv Imaging; 2014; 95(7-8):689-703. PubMed ID: 24951349
[TBL] [Abstract][Full Text] [Related]
2. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
Kim MN; Kim BK; Han KH; Kim SU
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
[TBL] [Abstract][Full Text] [Related]
3. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
[TBL] [Abstract][Full Text] [Related]
5. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
[TBL] [Abstract][Full Text] [Related]
7. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
8. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
Egger ME; Cannon RM; Metzger TL; Nowacki M; Kelly L; Tatum C; Scoggins CR; Callender GG; McMasters KM; Martin RC
J Am Coll Surg; 2013 Apr; 216(4):845-56; discussion 856-7. PubMed ID: 23415549
[TBL] [Abstract][Full Text] [Related]
9. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
10. Are recist criteria adequate in assessing the response to therapy in metastatic NEN?
Vullierme MP; Ruszniewski P; de Mestier L
Rev Endocr Metab Disord; 2021 Sep; 22(3):637-645. PubMed ID: 33871762
[TBL] [Abstract][Full Text] [Related]
11. [RECIST and the radiologist].
Cervera Deval J
Radiologia; 2014; 56(3):193-205. PubMed ID: 22902252
[TBL] [Abstract][Full Text] [Related]
12. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
13. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.
Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY
Oncology; 2015; 88(2):69-75. PubMed ID: 25277674
[TBL] [Abstract][Full Text] [Related]
14. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
15. Assessing Imaging Response to Therapy.
Minocha J; Lewandowski RJ
Radiol Clin North Am; 2015 Sep; 53(5):1077-88. PubMed ID: 26321455
[TBL] [Abstract][Full Text] [Related]
16. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment.
Morse B; Jeong D; Ihnat G; Silva AC
Abdom Radiol (NY); 2019 Feb; 44(2):766-774. PubMed ID: 30196362
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
18. CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.
Shafiei A; Bagheri M; Farhadi F; Apolo AB; Biassou NM; Folio LR; Jones EC; Summers RM
Radiol Imaging Cancer; 2021 May; 3(3):e200090. PubMed ID: 33874734
[TBL] [Abstract][Full Text] [Related]
19. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
